Arvinas Inc (ARVN)

$12.55 -0.12 (-0.95%)
Market Cap 748.85M
Revenue (ttm) 263.40M
Net Income (ttm) -198.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -75.51%
Debt to Equity Ratio 0.00
Volume 1,504,200
Avg Vol 2,579,784
Day's Range N/A - N/A
Shares Out 64.22M
Stochastic %K 93%
Beta 2.44
Analysts Sell
Price Target $12.20

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
McMillion1
McMillion1 Dec. 5 at 11:39 AM
$ARVN $20🚀
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 5 at 10:34 AM
$ARVN AtomicAlerts Scalp Alert Direction: SHORT Entry: $12.55 TP1: $11.85 | TP2: $11.15 | TP3: $10.45 Stop Loss: $13.15 👉 https://atomicalerts.com
1 · Reply
Iightning
Iightning Dec. 5 at 5:41 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ARVN Contract: Dec 19 $12.5C Entry: 0.75 Exit: 1.48 Return: +96.88% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 11:29 PM
1ightning® Premium Options Alert (Actionable) Ticker: $ARVN Contract: Dec 19 $12.5C Entry: 0.75 Exit: 1.48 Return: +96.88% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 10:31 PM
$ARVN Share Price: $12.55 Contract Selected: Jul 17, 2026 $14.0 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.23 – $2.72 Potential Upside: 65% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DanishViking92
DanishViking92 Dec. 4 at 9:00 PM
$ARVN nearly 13% of float shorted - we are primed for a squeeze.. and its going to be a big one!!
0 · Reply
DanishViking92
DanishViking92 Dec. 4 at 8:56 PM
$ARVN all i can say - know what you hold! 2 x Pre clinical data set for dec 6 (most likely resulting in a huge comeback move, this stock has been tumbling down for way too long) undervalued and outdated price targets. Its squeeze time!
0 · Reply
NakdEnergy
NakdEnergy Dec. 4 at 4:20 PM
$ARVN did we just hear their will be no definitive announcements till 2026 or is Monday still the target?
1 · Reply
SMILEYTROLLER
SMILEYTROLLER Dec. 4 at 4:10 PM
$ARVN calling P2 $CAPR like i said when it was mid 6s
0 · Reply
DanishViking92
DanishViking92 Dec. 4 at 4:04 PM
$ARVN
0 · Reply
Latest News on ARVN
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 9 days ago

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Nov 24, 2025, 7:00 AM EST - 11 days ago

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 3:01 PM EST - 4 weeks ago

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 4:00 PM EST - 4 weeks ago

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Arvinas to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:00 AM EST - 4 weeks ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 5 weeks ago

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 24, 2025, 4:00 PM EDT - 5 weeks ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2025, 4:00 PM EDT - 6 weeks ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

Oct 20, 2025, 4:15 AM EDT - 6 weeks ago

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

PFE

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 13, 2025, 7:00 AM EDT - 7 weeks ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 5, 2025, 2:00 PM EDT - 2 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 1, 2025, 7:00 AM EDT - 2 months ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

Sep 17, 2025, 5:50 PM EDT - 2 months ago

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

PFE

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Sep 17, 2025, 4:30 PM EDT - 2 months ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 9, 2025, 10:12 AM EDT - 3 months ago

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Aug 8, 2025, 4:05 PM EDT - 4 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:24 PM EDT - 4 months ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:00 AM EDT - 4 months ago

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 4:05 PM EDT - 4 months ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jul 9, 2025, 7:00 AM EDT - 5 months ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 13, 2025, 7:00 AM EDT - 6 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 6, 2025, 7:00 AM EDT - 6 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Jun 5, 2025, 8:28 AM EDT - 6 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

May 31, 2025, 8:06 AM EDT - 6 months ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 31, 2025, 8:00 AM EDT - 6 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 6 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 16, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 15, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 14, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 13, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 7 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

May 9, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

May 8, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

May 7, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

McMillion1
McMillion1 Dec. 5 at 11:39 AM
$ARVN $20🚀
0 · Reply
AtomicAIerts
AtomicAIerts Dec. 5 at 10:34 AM
$ARVN AtomicAlerts Scalp Alert Direction: SHORT Entry: $12.55 TP1: $11.85 | TP2: $11.15 | TP3: $10.45 Stop Loss: $13.15 👉 https://atomicalerts.com
1 · Reply
Iightning
Iightning Dec. 5 at 5:41 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ARVN Contract: Dec 19 $12.5C Entry: 0.75 Exit: 1.48 Return: +96.88% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 11:29 PM
1ightning® Premium Options Alert (Actionable) Ticker: $ARVN Contract: Dec 19 $12.5C Entry: 0.75 Exit: 1.48 Return: +96.88% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 10:31 PM
$ARVN Share Price: $12.55 Contract Selected: Jul 17, 2026 $14.0 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.23 – $2.72 Potential Upside: 65% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DanishViking92
DanishViking92 Dec. 4 at 9:00 PM
$ARVN nearly 13% of float shorted - we are primed for a squeeze.. and its going to be a big one!!
0 · Reply
DanishViking92
DanishViking92 Dec. 4 at 8:56 PM
$ARVN all i can say - know what you hold! 2 x Pre clinical data set for dec 6 (most likely resulting in a huge comeback move, this stock has been tumbling down for way too long) undervalued and outdated price targets. Its squeeze time!
0 · Reply
NakdEnergy
NakdEnergy Dec. 4 at 4:20 PM
$ARVN did we just hear their will be no definitive announcements till 2026 or is Monday still the target?
1 · Reply
SMILEYTROLLER
SMILEYTROLLER Dec. 4 at 4:10 PM
$ARVN calling P2 $CAPR like i said when it was mid 6s
0 · Reply
DanishViking92
DanishViking92 Dec. 4 at 4:04 PM
$ARVN
0 · Reply
DanishViking92
DanishViking92 Dec. 4 at 3:51 PM
$MIST come over to $ARVN we are green all day now because pre clinical cancer results are coming up (most likely monday) perfect swing trade opportunity because you are most likely able to buyback MIST before Pdufa decision which is set for dec 13 but most likely going to happen the week after! ARVN set for pre clinical results Saturday dec 6, but its the weekend so its most likely Monday or tomorrow.
0 · Reply
RocketshipCalls
RocketshipCalls Dec. 4 at 2:07 PM
$ARVN 109k buy!!!!
0 · Reply
Regulator06
Regulator06 Dec. 4 at 2:04 PM
$ARVN https://event.webcasts.com/starthere.jsp?ei=1744749&tp_key=b56c5c7738 if interested in the live audio presentation at 11am this morning
0 · Reply
RocketshipCalls
RocketshipCalls Dec. 4 at 1:29 PM
$ARVN we like this stock
0 · Reply
Stockwatcher9999
Stockwatcher9999 Dec. 4 at 1:15 PM
$SRPT - people who like biotech plays check out $ARVN . Do your own due diligence, im not gonna share mine its to long. $CAPR
0 · Reply
Iightning
Iightning Dec. 4 at 7:09 AM
1ightning® Premium Options Alert (Actionable) Ticker: $ARVN Contract: Dec 19 $14C Entry: 0.33 Exit: 0.44 Return: +35.95% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
DanishViking92
DanishViking92 Dec. 4 at 1:36 AM
$ARVN When breast cancer study was in early stage this stock rocketed from $20 to $80!! This tells me the new cancer drug results on Saturday could result in similar price movements - then $40-50 should be a possible goal short term
1 · Reply
Greatguns
Greatguns Dec. 4 at 1:11 AM
$ARVN
0 · Reply
DanishViking92
DanishViking92 Dec. 3 at 9:19 PM
$ARVN Strong day, strong close - definitely ready to squeeze! (Expecting an out of the blue kind of reaction, it seems like people are expecting nothing, but these early results are very important for the companies future!)
1 · Reply
DanishViking92
DanishViking92 Dec. 3 at 6:53 PM
$MIST this is totally normal, people leave because they dont want to take the risk.. remember many people bought at the bottom or below 2 dollars and are now exiting, actually not a bad strategy if you got money enough. But if you are broke as shit like me, you go all in here because you know its a no brainer and you have to take the chance. Im going all in after $ARVN data. Only got $3K now and would be nice to double that and put everything in here (if i can make in time before decision!) arvn pre clinical data for Alzheimers friday or monday (presentation Saturday) Biotechs are gambling! No matter what people tell you, it is calculated gambling. GL!
2 · Reply
diegosan21
diegosan21 Dec. 3 at 4:58 PM
A pharma rally with my babies $SRPT $SPRY $MLTX $SNDX $ARVN
1 · Reply
DanishViking92
DanishViking92 Dec. 3 at 2:49 PM
$ARVN could this be the next $CAPR ? Positive pre-clinical data might push this back above $50 or what do you think is possible? $$
0 · Reply